Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

Basit Öğe Kaydı
dc.authoridURUN, YUKSEL/0000-0002-9152-9887
dc.contributor.authorTural, Deniz
dc.contributor.authorArslan, Cagatay
dc.contributor.authorSelcukbiricik, Fatih
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorAkar, Emre
dc.contributor.authorErman, Mustafa
dc.contributor.authorUrun, Yuksel
dc.date.accessioned2024-05-19T14:40:59Z
dc.date.available2024-05-19T14:40:59Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractThis 5-year analysis of real-world data confirms the durable response and long-term survival with ICTs in a broader range of patients with metastatic urothelial carcinoma. After 24 months, PFS and OS curves remained nearly flat. The safety profile was consistent with previous reports, and no new safety signals were observed. Background: In this study, we report real-world results from the 5-year follow-up data of urothelial carcinoma patients treated with immune checkpoint blockade therapies (ICTs). Patients and Methods: Metastatic urothelial carcinoma patients treated with at least one course of ICT were included in the study. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS), progression-free survival (PFS), duration of treatment with ICT, and safety. Median follow-up, PFS, and OS were estimated by using the Kaplan-Meier method. Results: Data of 201 eligible patients were analyzed. The median age of the patients was 66 (37-86) years, and 156 (84.3%) were male. The majority of patients (94.6%) had Eastern Cooperative Oncology Group (ECOG) PS scores of 0 to 1 and primary tumor in the bladder was predominant (87.5%). The median follow-up time was 54 (1.15-65) months. The rate of complete response (CR) to ICT, partial response (PR) rate, and ORR were 10.4% (n = 21), 22.4% (n = 45), and 32.4% (n = 66), respectively. The median duration of response (DOR) was 34.8 months (95% confidence interval [CI], 29.2-42.1). Of the 66 patients who responded to treatment, 28 (42%) had an ongoing response at the time of the analysis. Median PFS and OS were 3.8 (2.6-5.8) months and 9.4 (7.4-11.4) months, respectively. The 5-year PFS and OS rates were 9.8% and 12.8%, respectively. Fifty-eight percent of patients experienced a treatment-related adverse event of any grade, and 33 (16.4%) patients had a grade 3 to 4 adverse event. Conclusion: This 5-year analysis of real-world data confirms the durable response and long-term survival with ICT in metastatic urothelial carcinoma patients.en_US
dc.identifier.doi10.1016/j.clgc.2022.11.019
dc.identifier.endpage341en_US
dc.identifier.issn1558-7673
dc.identifier.issn1938-0682
dc.identifier.issue3en_US
dc.identifier.pmid36641357en_US
dc.identifier.scopus2-s2.0-85146448744en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage334en_US
dc.identifier.urihttps://doi.org10.1016/j.clgc.2022.11.019
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5047
dc.identifier.volume21en_US
dc.identifier.wosWOS:001009264100001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Genitourinary Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectDurability Of Antitumor Activity And Safetyen_US
dc.subjectImmune Checkpoint Blockade Therapiesen_US
dc.subjectLong-Term Survivalen_US
dc.subjectMetastatic Urothelial Carcinomaen_US
dc.subjectOutcomesen_US
dc.titleFive-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practiceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu